Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01812005 · MORE INFO

Limitations, agreements, and source contact

Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · Source last updated 2018-06-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
Study had slow patient enrollment and was discontinued after only 14 patients were enrolled.
point Of Contact
email
Kristie.Blum@osumc.edu
organization
The Ohio State University James Comprehensive Cancer Center
phone
614-293-7807
title
Kristie Blum, MD
Complete source fields
certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
Study had slow patient enrollment and was discontinued after only 14 patients were enrolled.
point Of Contact
email
Kristie.Blum@osumc.edu
organization
The Ohio State University James Comprehensive Cancer Center
phone
614-293-7807
title
Kristie Blum, MD

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice